|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno-or squamous cell carcinoma显示文摘AIM:To determine whether-1195 A→G and/or-765 G→C polymorphisms in Cyclooxygenase-2(COX-2 ) may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population.METHODS:Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area.DNA was isolated from whole blood and used for genotyping.PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis.Odds ratios(OR) and 95% confldence intervals(CI) were estimated.RESULTS:The distribution of the-1195 A→G polymorphism was signif icantly different in esophageal cancer patients compared to controls.The-1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma(OR = 3.85, 95% CI:1.45-10.3) compared with the-1195 AA genotype as a reference.The-765 G→C genotype distribution was not different between the two groups.The GG/ GG haplotype was present more often in esophageal adenocarcinoma patients than in controls(OR = 3.45, 95% CI:1.24-9.58;with AG/AG as a reference).The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical signif icance.CONCLUSION:Presence of the COX-2-1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma. | Jón O Kristinsson Paul van Westerveld Rene HM te Morsche Hennie MJ Roelofs T Wobbes Ben JM Witteman Adriaan CITL Tan Martijn GH van Oijen Jan BMJ Jansen Wilbert HM Peters | 2009 | World Journal of Gastroenterology2009，15，28： | 11 |
| 2 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review显示文摘AIM:To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS:A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated.To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS:Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI:67%-73%) and 59% in RA (95%CI:58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI:1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI:1.3-1.52) and 1.13 (95%CI:1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION:One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence. | Herma H Fidder Maartje MJ Singendonk Mike van der Have Bas Oldenburg Martijn GH van Oijen | 2013 | World Journal of Gastroenterology2013，19，27： | 2 |
| 3 | Derivatives of cyclohexylamine and morpholine as volatile corrosion inhibitors显示文摘 | Vuorinene E Ngobeni P Van GH | 1994 | British Corrosion Journal1994，29，2： | 1 |
| 4 | Interruption of the Tnfrsf4/Tnfsf4 (OX4043X40L)pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice 显示文摘 | Van Wanrooij EJ Van Puijvelde GH De Vos P | 2007 | Arterioscler Throm Vase Biol2007，27，1： | 1 |
| 5 | Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies 显示文摘 | De Bock GH Van der Hage JA Putter H | 2006 | Eur J Cancer2006，42，3： | 1 |
| 6 | Low-intensity pulsed ultrasound af{ects human articular ehondrocytes in vitro 显示文摘 | Korstjens CM van der Rijt RH Albers GH el al | 2008 | Med Biol Eng Comput2008，46，12： | 1 |
| 7 | Is there still a place for dopamine in the modern intensive care unit显示文摘 | Debaveye YA Van den Berghe GH | | 0，，02： | 1 |
| 8 | Interruption of the Tnfrsf4/Tnfsf4(OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice显示文摘 | van Wanrooij EJ van Puijvelde GH de Vos P | 2007 | Arterioscler Thromb Vasc Biol2007，27，1： | 1 |
| 9 | Temporoal lobe epilepsy: the various MR appearances of histologically proven mesial temporal selerosis显示文摘 | Meiners LC van Gils A Jansen GH | 1994 | AJNR1994，15，： | 1 |
| 10 | A grading system for hi- ppoeampal sclerosis based on the degree of hippocampal mossy fiber sprouting显示文摘 | Proper EA Jansen GH Van Veelen CW | 2001 | Acta Neuropathol2001，101，： | 1 |
| 11 | Quantification of bone structuralparameters and mechanical competence at the distal radius显示文摘 | van Lenthe GH Mueller TL Wirth AJ | 2008 | J Orthop Trauma2008，22，8： | 1 |
| 12 | Radical ne-phrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma:a randomised trial显示文摘 | Mickisch GH Garin A van Poppel H | 2001 | Lancet2001，358，9286： | 1 |
| 13 | In- terruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein recep- tor-deficient mice 显示文摘 | van Wanrooij EJ van Puijvelde GH de Vos P | 2007 | Arterioscler Thromb Vasc Biol2007，27，1： | 1 |
| 14 | Isolated loco-region-al recurrence of breast cancer is more common in young patients andfollowing breast conserving therapy:long-term results of EuropeanOrganisation for Research and Treatment of Cancer studies显示文摘 | de Bock GH van der Hage JA Putter H | 2006 | Eur JCancer2006，42，3： | 1 |
| 15 | Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSVenhanced allergic inflammation显示文摘 | Barends M van Oosten M de Rond GH | 2004 | Infect Dis2004，189，： | 1 |
| 16 | Effects of mechanical forces on maintenance and adaptation of form in trabecular bone显示文摘 | Huiskes R Ruimerman R van Lenthe GH | 2000 | Nature2000，405，6787： | 1 |
| 17 | A standardized method for recording pattem-eleclrited elec- troretinograms in normal human subjects显示文摘 | Ringens PJ van Lith GH Vijfvinkel-Bruinenga S | 1984 | Ophthalmo- logica1984，188，2： | 1 |
| 18 | Temporal lobe epilepsy: the various MR appearances of histologically proven mesial temporal sclerosis 显示文摘 | Meiners LC van Gils A Jansen GH et ol | 1994 | Am J Neuroradiol1994，15，8： | 1 |
| 19 | Hyperhomoeysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease显示文摘 | Van den Berg M Boers GH Franken DG | 1995 | Eur J Clin Invest1995，25，3： | 1 |
| 20 | Bromfenac sodium, acetaminophen/oxycodone,ibuprofen, and placebo for relief of postoperative pain 显示文摘 | JOHNSON GH VAN WAGONER JD BROWN J | 1997 | Clin Ther1997，19，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员